2-Oxo-3-azabicyclo[3.1.0]hexane derivatives acting as ketohexokinase (KHK) inhibitors have been reported in a recent Hua Medicine Ltd. patent as potentially useful for the treatment of diabetes, fibrosis, obesity, neurological, metabolic, gastrointestinal, cardiovascular and renal diseases, among others.